Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Media Is Abbott's January Pullback a Good Time to Buy? Submitted by Thomas Hughes. First Published: 1/24/2026. 
At a Glance - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories (NYSE: ABT)'s January 2026 pullback makes the stock look attractively valued. The move—driven more by market angst than by company weakness—appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
The zone in question aligns with market action from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates The most that can be said about Abbott Laboratories' Q4 results and guidance is that a few metrics missed the market's expectations. Still, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth missed by several hundred basis points, but margin strength helped offset that shortfall: adjusted earnings per share (EPS) rose about 12%, slightly above consensus. Segment-level results highlighted the resilience of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted—Nutrition falling nearly 9%—but solid growth in Established Pharmaceuticals and Med Tech offset those declines. Established Pharmaceuticals grew about 9%, driven by generics and emerging markets, while Med Tech expanded roughly 12.3%, showing strength across subsegments. Margins were healthy, though they came in a bit below some analyst forecasts. A favorable product mix, strength in Med Tech, lower COVID-19 sales and operational improvements helped margins outperform earlier expectations. Looking ahead, the company expects earnings to grow roughly 10% in 2026, outpacing revenue growth and supporting continued capital returns. Abbott's capital return profile is a key part of the investment case. The company is a Dividend King, having raised its payout annually for more than 50 years, and appears positioned to continue that trend. The stock yields about 2.5% after the pullback, and the payout ratio is below 50% of consensus EPS, leaving cash flow available for share buybacks—an important offset to dilutive share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts highlighted the revenue miss, but no major rating or price-target changes were issued the morning of the earnings release. The prevailing view is that this fundamentally healthy company can continue returning capital while reinvesting in growth, and the medium-term growth outlook remains meaningful. MarketBeat's consensus price target implies roughly 30% upside, which could push the stock back to record levels; even the low-end targets suggest some upside potential. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions. The acquisition of Exact Sciences is one example of a deal that could broaden revenue and profit streams and add to the pipeline. The recent decline has been steep and could deepen, but institutions accumulated shares through 2025 and are likely buyers at discounted prices. Early technical support appears in the $105 to $110 range, though that support is not yet confirmed. A downside risk remains that ABT could drift to the low end of the buy zone—near $95 or below—before any sustained rebound.
| 
